<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">genort</journal-id><journal-title-group><journal-title xml:lang="ru">Гений ортопедии</journal-title><trans-title-group xml:lang="en"><trans-title>Genij Ortopedii</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1028-4427</issn><issn pub-type="epub">2542-131X</issn><publisher><publisher-name>ЦЕНТР ИЛИЗАРОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18019/1028-4427-2025-31-5-632-638</article-id><article-id custom-type="elpub" pub-id-type="custom">genort-3335</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>Особенности ортопедической патологии у больных нейрофиброматозом I типа в республике Башкортостан</article-title><trans-title-group xml:lang="en"><trans-title>Specific features of orthopedic pathology in neurofibromatosis type I patients of the Republic of Bashkortostan</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4091-382X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мустафин</surname><given-names>Р. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mustafin</surname><given-names>R. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рустам Наилевич Мустафин — кандидат медицинских наук, доцент кафедры</p><p>Уфа</p></bio><bio xml:lang="en"><p>Rustam N. Mustafin — Candidate of Medical Sciences, Associate Professor of the Department</p><p>Ufa</p></bio><email xlink:type="simple">ruji79@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>21</day><month>10</month><year>2025</year></pub-date><volume>31</volume><issue>5</issue><fpage>632</fpage><lpage>638</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мустафин Р.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Мустафин Р.Н.</copyright-holder><copyright-holder xml:lang="en">Mustafin R.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ilizarov-journal.com/jour/article/view/3335">https://www.ilizarov-journal.com/jour/article/view/3335</self-uri><abstract><sec><title>Введение</title><p>Введение. Нейрофиброматоз I типа (NF-1) — наследственный опухолевый синдром, характеризующийся не только развитием кожных, подкожных и плексиформных нейрофибром, глиом зрительных нервов и когнитивных расстройств, но и ортопедической патологией. Актуальность исследования особенностей клинических проявлений NF-1 обусловлена частым развитием скелетных аномалий у пациентов, требующих специфического подхода в лечении в связи с возможным наличием опухолеподобных процессов в областях поражения костей и суставов.</p><p>Цель работы — определить частоту встречаемости ортопедической патологии и особенности проявления характерных для заболевания признаков у больных NF-1 в Республике Башкортостан (РБ), сравнить полученные результаты с данными мировой статистики.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Материал для исследования — амбулаторные карты пациентов с клиническим диагнозом «нейрофиброматоз I типа», результаты лабораторных и инструментальных исследований. Проведен ретроспективный анализ частоты встречаемости основных клинических проявлений NF-1 и ортопедической патологии. Использована интерактивная таблица сопряженности 2 × 2 с вычислением статистик связи (критерий Пирсона χ2 ) с поправкой Йейтса на непрерывность, разработанная В.П. Леоновым, выполнен анализ четырехпольных таблиц сопряженности.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Частота встречаемости NF-1 в РБ в 2024 году составила 1:7407, что в 2,3 раза реже, чем в среднем по миру (1:3000 человек). Определены: развитие сколиоза — у 17,4 %, деформация грудной клетки — у 5,3 %, псевдоартроз — у 3 %, дисморфизм лица — у 9 %, низкий рост — у 13,8 % больных. Случаи остеопороза, асимметрии лица и дисплазии крыла клиновидной кости у больных NF-1 в  регионе не зарегистрированы. При помощи четырехпольных таблиц сопряженности определено статистически значимое отличие частоты встречаемости ортопедической патологии у больных NF-1 из РБ. Согласно ретроспективному анализу, частота встречаемости ортопедической патологии у больных NF-1 из РБ оказалась статистически значимо ниже, чем в среднем по миру, что свидетельствует о необходимости внесения консультации ортопеда в медико-экономические стандарты для своевременного выявления патологии и назначения лечения.</p></sec><sec><title>Заключение</title><p>Заключение. Анализ особенностей проявлений ортопедической патологии у больных NF-1 из РБ показал сравнимую с мировыми данными частоту встречаемости деформации грудной клетки, сколиоза, низкого роста и псевдоартроза. Однако у пациентов с NF-1 из РБ определена достоверно более редкая регистрация скелетных аномалий в целом, дисморфизма лица, макроцефалии. Данных об остеопорозе, асимметрии лица и дисплазии крыла клиновидной кости, характерных для больных NF-1, в проанализированной группе не обнаружено. У больных NF-1 с ортопедической патологией выявлены более частые трудности в обучении в сравнении со всей группой пациентов с NF-1 из РБ.</p></sec></abstract><trans-abstract xml:lang="en"><p>Background Neurofibromatosis type 1 (NF-1) is a hereditary tumor syndrome characterized by cutaneous, subcutaneous and plexiform neurofibromas, optic nerve gliomas, cognitive disorders and can be associated with orthopedic pathology. Clinical manifestations of NF-1 include skeletal abnormalities requiring a specific approach to treatment of the tumor-like processes in the involved bones and joints.</p><p>The objective was to determine the frequency of orthopedic pathology and clinical manifestations of the disease in NF-1 patients seen in the Republic of Bashkortostan (RB) and make international comparisons.</p><p>Material and methods Outpatient records of patients with a clinical diagnosis of NF-I, the results of laboratory and  instrumentation studies were examined. A retrospective analysis of the frequency of  occurrence of the main clinical manifestations of NF-1 and orthopedic pathology was conducted. An interactive 2 × 2 contingency table was used for calculation of association statistics (Pearson χ2 criterion) with the Yates correction for continuity developed by V.P. Leonov and four-field contingency tables were analyzed.</p><p>Results and discussion The incidence rate of NF-1 was 1:7407 by 2024 in the RB, which is 2.3 times less than the world average (1:3000 people). Associated malformations included scoliosis seen in 17.4 %, chest deformity observed in 5.3 %, pseudoarthrosis in 3 %, facial dysmorphism in 9 %, short stature in 13.8 % of patients. Osteoporosis, facial asymmetry and sphenoid wing dysplasia were not observed in NF-1 patients in the region. A statistically significant difference in the frequency of occurrence of orthopedic pathology was determined in patients with NF-1 from the RB using four-field contingency tables. A retrospective analysis showed a statistically lower incidence of orthopedic pathology in NF-1 patients of RB as compared to the world average which indicated the need to include orthopedic consultation in medical and economic standards for the timely detection of pathology and treatment.</p><p>Conclusion Analysis of orthopedic pathology in NF-1 patients from RB showed the occurrence of  chest deformity, scoliosis, short stature and pseudoarthrosis being comparable with world data. Skeletal anomalies, facial dysmorphism and macrocephaly were not common for NF-1 patients of RB. No cases of osteoporosis, facial  asymmetry and sphenoid wing dysplasia being characteristic of NF-1 patients were detected in  the  patients. Learning difficulties were more common for NF-1 patients with orthopedic pathology as compared to NF-1 patients of RB.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>деформация грудной клетки</kwd><kwd>нейрофиброматоз I типа</kwd><kwd>остеопороз</kwd><kwd>псевдоартроз</kwd><kwd>сколиоз</kwd><kwd>частота встречаемости</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chest wall deformity</kwd><kwd>neurofibromatosis type 1</kwd><kwd>osteoporosis</kwd><kwd>pseudoarthrosis</kwd><kwd>scoliosis</kwd><kwd>frequency of occurrence</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Автор заявляет об отсутствии финансирования при проведении исследования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chai P, Luo Y, Zhou C, et al. Clinical characteristics and mutation Spectrum of NF1 in 12 Chinese families with orbital/periorbital plexiform Neurofibromatosis type 1. BMC Med Genet. 2019;20(1):158. doi: 10.1186/s12881-019-0877-9.</mixed-citation><mixed-citation xml:lang="en">Chai P, Luo Y, Zhou C, et al. Clinical characteristics and mutation Spectrum of NF1 in 12 Chinese families with orbital/periorbital plexiform Neurofibromatosis type 1. BMC Med Genet. 2019;20(1):158. doi: 10.1186/s12881-019-0877-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lee TJ, Chopra M, Kim RH, et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18(1):292. doi: 10.1186/s13023-023-02911-2.</mixed-citation><mixed-citation xml:lang="en">Lee TJ, Chopra M, Kim RH, et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18(1):292. doi: 10.1186/s13023-023-02911-2.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Crow AJD, Janssen JM, Marshall C, et al. A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1. Am J Med Genet A. 2022;188(8):2277-2292. doi: 10.1002/ajmg.a.62773.</mixed-citation><mixed-citation xml:lang="en">Crow AJD, Janssen JM, Marshall C, et al. A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1. Am J Med Genet A. 2022;188(8):2277-2292. doi: 10.1002/ajmg.a.62773.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Schepper S, Maertens O, Callens T, et al. Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol. 2008;128(4):1050-1053. doi: 10.1038/sj.jid.5701095.</mixed-citation><mixed-citation xml:lang="en">De Schepper S, Maertens O, Callens T, et al. Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol. 2008;128(4):1050-1053. doi: 10.1038/sj.jid.5701095.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. doi: 10.1038/nrdp.2017.4.</mixed-citation><mixed-citation xml:lang="en">Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. doi: 10.1038/nrdp.2017.4.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am. 2019;103(6):1035-1054. doi: 10.1016/j.mcna.2019.07.004.</mixed-citation><mixed-citation xml:lang="en">Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am. 2019;103(6):1035-1054. doi: 10.1016/j.mcna.2019.07.004.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Miraglia E, Moliterni E, Iacovino C, et al. Cutaneous manifestations in neurofibromatosis type 1. Clin Ter. 2020;171(5):e371-e377. doi: 10.7417/CT.2020.2242.</mixed-citation><mixed-citation xml:lang="en">Miraglia E, Moliterni E, Iacovino C, et al. Cutaneous manifestations in neurofibromatosis type 1. Clin Ter. 2020;171(5):e371-e377. doi: 10.7417/CT.2020.2242.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Glombova M, Petrak B, Lisy J, et al. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1. Brain Dev. 2019;41(8):678-690. doi: 10.1016/j.braindev.2019.04.003.</mixed-citation><mixed-citation xml:lang="en">Glombova M, Petrak B, Lisy J, et al. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1. Brain Dev. 2019;41(8):678-690. doi: 10.1016/j.braindev.2019.04.003.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wu F, Ji X, Shen M, et al. Prevalence, clinical characteristics and outcomes of seizures in neurofibromatosis type 1: A systematic review and single arm meta-analysis. Epilepsy Res. 2024;208:107476. doi: 10.1016/j.eplepsyres.2024.107476.</mixed-citation><mixed-citation xml:lang="en">Wu F, Ji X, Shen M, et al. Prevalence, clinical characteristics and outcomes of seizures in neurofibromatosis type 1: A systematic review and single arm meta-analysis. Epilepsy Res. 2024;208:107476. doi: 10.1016/j.eplepsyres.2024.107476.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lim Z, Gu TY, Tai BC, Puhaindran ME. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis. World J Surg Oncol. 2024;22(1):14. doi: 10.1186/s12957-023-03296-z.</mixed-citation><mixed-citation xml:lang="en">Lim Z, Gu TY, Tai BC, Puhaindran ME. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis. World J Surg Oncol. 2024;22(1):14. doi: 10.1186/s12957-023-03296-z.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D, Zhang BH, Wen X, et al. Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: a systemic review and meta-analysis. Eur Spine J. 2024;33(7):2646-2665. doi: 10.1007/s00586-024-08194-w.</mixed-citation><mixed-citation xml:lang="en">Wang D, Zhang BH, Wen X, et al. Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: a systemic review and meta-analysis. Eur Spine J. 2024;33(7):2646-2665. doi: 10.1007/s00586-024-08194-w.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, Cagozzi L, Garavelli L, Bernasconi S. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2003;16 Suppl 2:289-292.</mixed-citation><mixed-citation xml:lang="en">Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, Cagozzi L, Garavelli L, Bernasconi S. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2003;16 Suppl 2:289-292.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Stevenson DA, Little D, Armstrong L, et al. Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium. J Pediatr Orthop. 2013;33(3):269-275. doi: 10.1097/BPO.0b013e31828121b8.</mixed-citation><mixed-citation xml:lang="en">Stevenson DA, Little D, Armstrong L, et al. Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium. J Pediatr Orthop. 2013;33(3):269-275. doi: 10.1097/BPO.0b013e31828121b8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mladenov KV, Spiro AS, Krajewski KL, et al. Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1). Childs Nerv Syst. 2020;36(10):2409-2425. doi: 10.1007/s00381-020-04775-4.</mixed-citation><mixed-citation xml:lang="en">Mladenov KV, Spiro AS, Krajewski KL, et al. Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1). Childs Nerv Syst. 2020;36(10):2409-2425. doi: 10.1007/s00381-020-04775-4.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chauvel-Picard J, Lion-Francois L, Beuriat PA, et al. Craniofacial bone alterations in patients with neurofibromatosis type 1. Childs Nerv Syst. 2020;36(10):2391-2399. doi: 10.1007/s00381-020-04749-6.</mixed-citation><mixed-citation xml:lang="en">Chauvel-Picard J, Lion-Francois L, Beuriat PA, et al. Craniofacial bone alterations in patients with neurofibromatosis type 1. Childs Nerv Syst. 2020;36(10):2391-2399. doi: 10.1007/s00381-020-04749-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Luna EB, Janini ME, Lima F, et al. Craniomaxillofacial morphology alterations in children, adolescents and adults with neurofibromatosis 1: A cone beam computed tomography analysis of a Brazilian sample. Med Oral Patol Oral Cir Bucal. 2018;23(2):e168-e179. doi: 10.4317/medoral.22155.</mixed-citation><mixed-citation xml:lang="en">Luna EB, Janini ME, Lima F, et al. Craniomaxillofacial morphology alterations in children, adolescents and adults with neurofibromatosis 1: A cone beam computed tomography analysis of a Brazilian sample. Med Oral Patol Oral Cir Bucal. 2018;23(2):e168-e179. doi: 10.4317/medoral.22155.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Francis L, Subramanyam R, Mahmoud M. Severe spinal and chest deformity secondary to neurofibromatosis. Can J Anaesth. 2016;63(4):488-489. doi: 10.1007/s12630-015-0543-4.</mixed-citation><mixed-citation xml:lang="en">Francis L, Subramanyam R, Mahmoud M. Severe spinal and chest deformity secondary to neurofibromatosis. Can J Anaesth. 2016;63(4):488-489. doi: 10.1007/s12630-015-0543-4.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kaspiris A, Vasiliadis E, Iliopoulos ID, et al. Bone mineral density, vitamin D and osseous metabolism indices in neurofibromatosis type 1: A systematic review and meta-analysis. Bone. 2024;180:116992. doi: 10.1016/j.bone.2023.116992.</mixed-citation><mixed-citation xml:lang="en">Kaspiris A, Vasiliadis E, Iliopoulos ID, et al. Bone mineral density, vitamin D and osseous metabolism indices in neurofibromatosis type 1: A systematic review and meta-analysis. Bone. 2024;180:116992. doi: 10.1016/j.bone.2023.116992.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rhodes SD, Yang FC. Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1. Curr Osteoporos Rep. 2016;14(1):10-15. doi: 10.1007/s11914-016-0298-z.</mixed-citation><mixed-citation xml:lang="en">Rhodes SD, Yang FC. Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1. Curr Osteoporos Rep. 2016;14(1):10-15. doi: 10.1007/s11914-016-0298-z.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tolliver S, Smith ZI, Silverberg N. The genetics and diagnosis of pediatric neurocutaneous disorders: Neurofibromatosis and tuberous sclerosis complex. Clin Dermatol. 2022;40(4):374-382. doi: 10.1016/j.clindermatol.2022.02.010.</mixed-citation><mixed-citation xml:lang="en">Tolliver S, Smith ZI, Silverberg N. The genetics and diagnosis of pediatric neurocutaneous disorders: Neurofibromatosis and tuberous sclerosis complex. Clin Dermatol. 2022;40(4):374-382. doi: 10.1016/j.clindermatol.2022.02.010.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yue X, Zhao X, Dai Y, Yu L. Leopard syndrome: the potential cardiac defect underlying skin phenotypes. Hereditas. 2021;158(1):34. doi: 10.1186/s41065-021-00199-5.</mixed-citation><mixed-citation xml:lang="en">Yue X, Zhao X, Dai Y, Yu L. Leopard syndrome: the potential cardiac defect underlying skin phenotypes. Hereditas. 2021;158(1):34. doi: 10.1186/s41065-021-00199-5.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lalor L, Davies OMT, Basel D, Siegel DH. Café au lait spots: When and how to pursue their genetic origins. Clin Dermatol. 2020;38(4):421 431. doi: 10.1016/j.clindermatol.2020.03.005.</mixed-citation><mixed-citation xml:lang="en">Lalor L, Davies OMT, Basel D, Siegel DH. Café au lait spots: When and how to pursue their genetic origins. Clin Dermatol. 2020;38(4):421 431. doi: 10.1016/j.clindermatol.2020.03.005.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yotsumoto Y, Harada A, Tsugawa J, et al. Infantile macrocephaly and multiple subcutaneous lipomas diagnosed with PTEN hamartoma tumor syndrome: A case report. Mol Clin Oncol. 2020;12(4):329-335. doi: 10.3892/mco.2020.1988.</mixed-citation><mixed-citation xml:lang="en">Yotsumoto Y, Harada A, Tsugawa J, et al. Infantile macrocephaly and multiple subcutaneous lipomas diagnosed with PTEN hamartoma tumor syndrome: A case report. Mol Clin Oncol. 2020;12(4):329-335. doi: 10.3892/mco.2020.1988.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Xu ZX, Jiang LX, Chen YR, et al. Clinical features, diagnosis, and treatment of Peutz-Jeghers syndrome: Experience with 566 Chinese cases. World J Gastroenterol. 2023;29(10):1627-1637. doi: 10.3748/wjg.v29.i10.1627.</mixed-citation><mixed-citation xml:lang="en">Xu ZX, Jiang LX, Chen YR, et al. Clinical features, diagnosis, and treatment of Peutz-Jeghers syndrome: Experience with 566 Chinese cases. World J Gastroenterol. 2023;29(10):1627-1637. doi: 10.3748/wjg.v29.i10.1627.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kavamura MI, Leoni C, Neri G. Dermatological manifestations, management, and care in RASopathies. Am J Med Genet C Semin Med Genet. 2022;190(4):452-458. doi: 10.1002/ajmg.c.32027.</mixed-citation><mixed-citation xml:lang="en">Kavamura MI, Leoni C, Neri G. Dermatological manifestations, management, and care in RASopathies. Am J Med Genet C Semin Med Genet. 2022;190(4):452-458. doi: 10.1002/ajmg.c.32027.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sánchez Marco SB, López Pisón J, Calvo Escribano C, et al. Neurological manifestations of neurofibromatosis type 1: our experience. Neurologia (Engl Ed). 2022;37(5):325-333. doi: 10.1016/j.nrleng.2019.05.008.</mixed-citation><mixed-citation xml:lang="en">Sánchez Marco SB, López Pisón J, Calvo Escribano C, et al. Neurological manifestations of neurofibromatosis type 1: our experience. Neurologia (Engl Ed). 2022;37(5):325-333. doi: 10.1016/j.nrleng.2019.05.008.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">de Brons B, Dhaenens B, van Minkelen R, Oostenbrink R. Identification of the Determinants of Plexiform Neurofibroma Morbidity in Pediatric and Young Adult Neurofibromatosis Type 1 Patients: A Pilot Multivariate Approach. Cancers (Basel). 2025;17(1):123. doi: 10.3390/cancers17010123.</mixed-citation><mixed-citation xml:lang="en">de Brons B, Dhaenens B, van Minkelen R, Oostenbrink R. Identification of the Determinants of Plexiform Neurofibroma Morbidity in Pediatric and Young Adult Neurofibromatosis Type 1 Patients: A Pilot Multivariate Approach. Cancers (Basel). 2025;17(1):123. doi: 10.3390/cancers17010123.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pratama AAT, Atmaja MHS. The role of multimodality imaging in diffuse pelvicoabdominal plexiform neurofibroma: A rare case report. Radiol Case Rep. 2024;19(12):5605-5611. doi: 10.1016/j.radcr.2024.08.037.</mixed-citation><mixed-citation xml:lang="en">Pratama AAT, Atmaja MHS. The role of multimodality imaging in diffuse pelvicoabdominal plexiform neurofibroma: A rare case report. Radiol Case Rep. 2024;19(12):5605-5611. doi: 10.1016/j.radcr.2024.08.037.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Yue X, Stauff E, Boyapati S, et al. PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. Pharmaceuticals (Basel). 2024;17(6):685. doi: 10.3390/ph17060685.</mixed-citation><mixed-citation xml:lang="en">Yue X, Stauff E, Boyapati S, et al. PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. Pharmaceuticals (Basel). 2024;17(6):685. doi: 10.3390/ph17060685.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ota M, Nobeyama Y, Asahina A. Real-world Settings for the Surgical Treatment of Neurofibroma in Patients with Neurofibromatosis Type 1. JMA J. 2024;7(2):205-212. doi: 10.31662/jmaj.2023-0161.</mixed-citation><mixed-citation xml:lang="en">Ota M, Nobeyama Y, Asahina A. Real-world Settings for the Surgical Treatment of Neurofibroma in Patients with Neurofibromatosis Type 1. JMA J. 2024;7(2):205-212. doi: 10.31662/jmaj.2023-0161.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nishida Y, Nonobe N, Kidokoro H, et al. Selumetinib for symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1: the first single-center real-world case series in Japan. Jpn J Clin Oncol. 2025:hyae184. doi: 10.1093/jjco/hyae184.</mixed-citation><mixed-citation xml:lang="en">Nishida Y, Nonobe N, Kidokoro H, et al. Selumetinib for symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1: the first single-center real-world case series in Japan. Jpn J Clin Oncol. 2025:hyae184. doi: 10.1093/jjco/hyae184.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Gross AM, Achée C, Hart SE, et al. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Future Oncol. 2024;20(14):877-890. doi: 10.2217/fon-2023-0565.</mixed-citation><mixed-citation xml:lang="en">Gross AM, Achée C, Hart SE, et al. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Future Oncol. 2024;20(14):877-890. doi: 10.2217/fon-2023-0565.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Han Y, Li B, Yu X, et al. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. J Neurol. 2024;271(5):2379-2389. doi: 10.1007/s00415-024-12301-8.</mixed-citation><mixed-citation xml:lang="en">Han Y, Li B, Yu X, et al. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. J Neurol. 2024;271(5):2379-2389. doi: 10.1007/s00415-024-12301-8.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gross AM, O'Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nat Med. 2025;31(1):105-115. doi: 10.1038/s41591-024-03361-4.</mixed-citation><mixed-citation xml:lang="en">Gross AM, O'Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nat Med. 2025;31(1):105-115. doi: 10.1038/s41591-024-03361-4.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Jackson S, Baker EH, Gross AM, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neurooncol Adv. 2020;2(1):vdaa095. doi: 10.1093/noajnl/vdaa095.</mixed-citation><mixed-citation xml:lang="en">Jackson S, Baker EH, Gross AM, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neurooncol Adv. 2020;2(1):vdaa095. doi: 10.1093/noajnl/vdaa095.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
